US launches Precision Strike Missiles in Iran war in first combat use

The U.S. military has used Lockheed Martin’s long-range Precision Strike Missile (PrSM) in combat for the first time against Iranian targets as part of Operation Epic Fury, launching the GPS-guided, fragmentation-warhead munition from M142 HIMARS with an advertised range of roughly 250 miles. The deployment follows U.S. Army test and production-ramp efforts with Lockheed (White Sands tests and HIMARS/MLRS firings) and accompanies broader strikes that the Pentagon says have destroyed over 2,000 Iranian targets, including a sunk frigate; the move strengthens the operational case for PrSM and may support defense contractors while raising geopolitical risk that could drive risk-off positioning by investors.

Analysis

Market structure: Lockheed Martin (LMT) is an immediate beneficiary — fielding PrSM in combat converts R&D into a marketing/ordering advantage versus peers (RTX, NOC, GD) and should lift bid activity and backlog visibility over the next 3–12 months. Civil sectors (airlines, reinsurers) are potential losers from higher geopolitical risk and oil volatility; expect a risk‑off impulse to credit spreads and safe‑haven flows initially.

Risk assessment: Tail risks include broad regional escalation (low prob, high impact) that could push Brent >$20/bbl above spot within weeks and force large re‑prioritization of capital; procurement or export‑control changes are medium‑probability second‑order risks that could delay revenues for suppliers. Time horizons: days (risk‑off and vols spike), weeks–months (DOD order/capacity signals), quarters–years (sustained production ramp and margin realization dependent on supply chain scale‑up).

Trade implications: Favor direct defense exposure with disciplined sizing: LMT and RTX will outgrow commercial peers if supplemental funding arrives; options can express view while limiting cash. Cross‑asset: buy short‑dated protection (VIX calls or SPX put spreads) ahead of expected congressional/supplemental votes; expect Treasuries to rally on headline escalation, compressing intermediate yields.

Contrarian angles: The market may be pricing this as a durable demand shock while ignoring production bottlenecks (semis, specialized steel, warhead fuzes) that can delay revenue recognition 6–18 months. Also one combat deployment is a marketing event — absent confirmed multi-year orders the upside is likely limited; political backlash could shift funding away from offensive munitions into defenses/ABM.

Key Decisions for Investors

• Establish a 2–3% long equity position in LMT (ticker LMT) sized to portfolio risk budget; target +12–18% upside over 3–12 months if DOD/FMS orders announced, place a hard stop-loss at -8% from entry to guard against escalation shock.
• Buy a 6-month LMT call spread (buy ATM, sell ATM+12%) sized to 1% of portfolio to capture upside while capping premium; take profit on a confirmed contract award (>=$500m) or at 6 months, whichever comes first.
• Pair trade: go long RTX (2% position) and short BA (1.5%) to express relative strength in defense vs. civil aerospace over 3–9 months; unwind on (a) signed supplemental funding >$5bn for missiles or (b) if oil spikes >+$20/bbl intraday.
• Allocate 0.5–1% to a short‑dated tail hedge: buy 30‑45 day VIX call spread or 2% notional SPX 3‑month 5% OTM put spread; deploy ahead of major congressional votes (expect announcements within 14–60 days) and liquidate after resolution or a 25% move in realized vol.